- Home
- JXG vs APVO Comparison
JXG vs APVO Comparison
Compare JXG & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXG
- APVO
- Stock Information
- Founded
- JXG N/A
- APVO 2016
- Country
- JXG China
- APVO United States
- Employees
- JXG N/A
- APVO N/A
- Industry
- JXG
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- JXG
- APVO Health Care
- Exchange
- JXG Nasdaq
- APVO Nasdaq
- Market Cap
- JXG 4.7M
- APVO 4.1M
- IPO Year
- JXG N/A
- APVO N/A
- Fundamental
- Price
- JXG $0.94
- APVO $1.50
- Analyst Decision
- JXG
- APVO Strong Buy
- Analyst Count
- JXG 0
- APVO 1
- Target Price
- JXG N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- JXG 118.3K
- APVO 162.7K
- Earning Date
- JXG 05-15-2025
- APVO 11-06-2025
- Dividend Yield
- JXG N/A
- APVO N/A
- EPS Growth
- JXG N/A
- APVO N/A
- EPS
- JXG 0.86
- APVO N/A
- Revenue
- JXG $49,840,288.00
- APVO N/A
- Revenue This Year
- JXG N/A
- APVO N/A
- Revenue Next Year
- JXG N/A
- APVO N/A
- P/E Ratio
- JXG $1.06
- APVO N/A
- Revenue Growth
- JXG 56.53
- APVO N/A
- 52 Week Low
- JXG $0.55
- APVO $1.54
- 52 Week High
- JXG $8.40
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- JXG 37.93
- APVO 25.88
- Support Level
- JXG $0.85
- APVO $1.56
- Resistance Level
- JXG $1.04
- APVO $1.73
- Average True Range (ATR)
- JXG 0.08
- APVO 0.14
- MACD
- JXG 0.01
- APVO 0.02
- Stochastic Oscillator
- JXG 39.33
- APVO 0.00
About JXG JX Luxventure Limited Common Stock
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.